Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate

J. J. Goedert; C. S. Rabkin; A. R. Cohen; C. M. Kessler; S. Eichinger; S. V. Seremetis; L. M. Aledort; F. J. Yellin; P. S. Rosenberg

doi:10.1016/S0140-6736(94)92345-0

Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate

J. J. Goedert, C. S. Rabkin, A. R. Cohen, C. M. Kessler, S. Eichinger, S. V. Seremetis, L. M. Aledort, F. J. Yellin, P. S. Rosenberg

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1·34 per month) and cumulative (1·01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1·49 and 1·03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.

Original language	English
Pages (from-to)	791-792
Number of pages	2
Journal	The Lancet
Volume	344
Issue number	8925
DOIs	https://doi.org/10.1016/S0140-6736(94)92345-0
State	Published - 17 Sep 1994

Access to Document

10.1016/S0140-6736(94)92345-0

Cite this

@article{cf053dcb1d4044d985d2821b23ca196b,

title = "Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate",

abstract = "In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1·34 per month) and cumulative (1·01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1·49 and 1·03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.",

author = "Goedert, {J. J.} and Rabkin, {C. S.} and Cohen, {A. R.} and Kessler, {C. M.} and S. Eichinger and Seremetis, {S. V.} and Aledort, {L. M.} and Yellin, {F. J.} and Rosenberg, {P. S.}",

note = "Funding Information: We thank Dr Yoshio Aso and Dr Kiyoshi Kurokawa for their support and encouragement. This work was supported in part by a programme project grant of the Ministry of Health and Welfare, Japan.",

year = "1994",

month = sep,

day = "17",

doi = "10.1016/S0140-6736(94)92345-0",

language = "English",

volume = "344",

pages = "791--792",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8925",

}

TY - JOUR

T1 - Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate

AU - Goedert, J. J.

AU - Rabkin, C. S.

AU - Cohen, A. R.

AU - Kessler, C. M.

AU - Eichinger, S.

AU - Seremetis, S. V.

AU - Aledort, L. M.

AU - Yellin, F. J.

AU - Rosenberg, P. S.

N1 - Funding Information: We thank Dr Yoshio Aso and Dr Kiyoshi Kurokawa for their support and encouragement. This work was supported in part by a programme project grant of the Ministry of Health and Welfare, Japan.

PY - 1994/9/17

Y1 - 1994/9/17

N2 - In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1·34 per month) and cumulative (1·01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1·49 and 1·03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.

AB - In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1·34 per month) and cumulative (1·01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1·49 and 1·03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0028093461&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(94)92345-0

DO - 10.1016/S0140-6736(94)92345-0

M3 - Article

C2 - 7916077

AN - SCOPUS:0028093461

SN - 0140-6736

VL - 344

SP - 791

EP - 792

JO - The Lancet

JF - The Lancet

IS - 8925

ER -

Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate

Abstract

Access to Document

Fingerprint

Cite this